Matthew S. Davids, MD, MMSc, discusses recent shifts in the chronic lymphocytic leukemia paradigm with the use of novel therapies and the need to increase personalized treatment with these agents.
Fee-for-service tends to result in a surplus of care and unnecessary medical expense, but it probably won’t disappear from the landscape soon.
Joseph D. Rosenblatt, MD, discusses how advances made in chronic lymphocytic leukemia are changing the outlook for patients and predicts what can be accomplished in the near future.
During an OncLive Peer Exchange®, a panel of CLL experts review findings from studies presented at the 2018 American Society of Hematology meeting in December: iLLUMINATE, Alliance A041202, and ECOG E1912.
Matthew S. Davids, MD, MMSc, discusses methods for choosing between frontline therapies for patients with newly diagnosed chronic lymphocytic leukemia and highlights anticipated research in the field.
A supplemental new drug application has been filed for the combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia who also have coexisting medical conditions.
Based on the crucial role of BCL-2 family proteins in apoptosis regulation, targeting these proteins using BCL-2 inhibitors offers a potentially new therapeutic option for patients with various types of hematologic malignancies and, more recently, patients with solid tumors.
New agents in chronic lymphocytic leukemia are significantly strengthening the armamentarium, particularly next-generation BTK and PI3K inhibitors, and although toxicities remain an issue, tolerability may be improving.
The day is approaching that chemotherapy may be unnecessary for the treatment of patients with chronic lymphocytic leukemia.
Nicole Lamanna, MD, highlights the latest MURANO data in CLL, delving into the need for more studies to test the feasibility of time-limited treatment in this patient population.